Compare · LIVN vs STEX
LIVN vs STEX
Side-by-side comparison of LivaNova PLC (LIVN) and Streamex Corp. (STEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and STEX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.31B, about 44.3x STEX ($97.3M).
- Over the past year, LIVN is up 73.6% and STEX is down 85.2% - LIVN leads by 158.8 points.
- LIVN has been more active in the news (18 items in the past 4 weeks vs 9 for STEX).
- LIVN has more recent analyst coverage (20 ratings vs 1 for STEX).
- Company
- LivaNova PLC
- Streamex Corp.
- Price
- $78.50-1.23%
- $0.93-8.97%
- Market cap
- $4.31B
- $97.3M
- 1M return
- +8.65%
- -6.16%
- 1Y return
- +73.60%
- -85.19%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 18
- 9
- Recent ratings
- 20
- 1
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest LIVN
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)
- Director Story Brooke covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 57% to 9,788 units (SEC Form 4)
Latest STEX
- Interim Executive Chairman Lekstrom Morgan Lee bought $49,750 worth of shares (50,000 units at $0.99) (SEC Form 4)
- Chief Investment Officer Williams Mitchell Young sold $24,915 worth of shares (23,810 units at $1.05), decreasing direct ownership by 0.78% to 3,013,838 units (SEC Form 4) to satisfy withholding obligation
- Amendment: SEC Form 4 filed by Interim Executive Chairman Lekstrom Morgan Lee
- Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)
- Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Interim Executive Chairman Lekstrom Morgan Lee bought $49,980 worth of shares (34,000 units at $1.47) (SEC Form 4)
- Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset
- Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design
- Director Marciano Anthony Mark bought $20,052 worth of shares (17,745 units at $1.13), increasing direct ownership by 18% to 117,745 units (SEC Form 4)